Literature DB >> 7585144

Prevention of breast tumour development in vivo by downregulation of the p185neu receptor.

M Katsumata1, T Okudaira, A Samanta, D P Clark, J A Drebin, P Jolicoeur, M I Greene.   

Abstract

Certain strains of transgenic mice that express the rat neu oncogene (neuT) in mammary epithelial cells develop breast tumours at an average of 44 weeks of age. In this study, intraperitoneal injection of a monoclonal anti-receptor antibody specific for the rat neuT oncogene product dramatically affected tumour development in these transgenic mice in a dose-dependent manner. A significant proportion (50%) of mice, when injected with anti-receptor antibodies, did not develop tumours even after 90 weeks of age. The phosphotyrosine levels of the membrane fraction of breast tissues in the anti-receptor antibody-treated mice were almost completely abolished when a higher dose of antibodies was used. This study demonstrates, for the first time, that immunologic manipulation of an oncogene product can effectively prevent the development of tumours in a rodent transgenic model.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585144     DOI: 10.1038/nm0795-644

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  23 in total

Review 1.  ErbB receptors: from oncogenes to targeted cancer therapies.

Authors:  Hongtao Zhang; Alan Berezov; Qiang Wang; Geng Zhang; Jeffrey Drebin; Ramachandran Murali; Mark I Greene
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

2.  Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.

Authors:  Annalisa Astolfi; Lorena Landuzzi; Giordano Nicoletti; Carla De Giovanni; Stefania Croci; Arianna Palladini; Silvano Ferrini; Manuela Iezzi; Piero Musiani; Federica Cavallo; Guido Forni; Patrizia Nanni; Pier-Luigi Lollini
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

3.  Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury.

Authors:  Margarita Calvo; Ning Zhu; Christoforos Tsantoulas; Zhenzhong Ma; John Grist; Jeffrey A Loeb; David L H Bennett
Journal:  J Neurosci       Date:  2010-04-14       Impact factor: 6.167

4.  Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinases.

Authors:  B W Park; D M O'Rourke; Q Wang; J G Davis; A Post; X Qian; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

Review 5.  Immunologic approaches to inhibiting cell-surface-residing oncoproteins in human tumors.

Authors:  D M O'Rourke; M I Greene
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 6.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

7.  Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens.

Authors:  M L Disis; F M Shiota; M A Cheever
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

8.  Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.

Authors:  Claudia Curcio; Emma Di Carlo; Raphael Clynes; Mark J Smyth; Katia Boggio; Elena Quaglino; Michela Spadaro; Mario P Colombo; Augusto Amici; Pier-Luigi Lollini; Piero Musiani; Guido Forni
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

9.  Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors.

Authors:  Yasuhiro Nagai; Hiromichi Tsuchiya; E Aaron Runkle; Peter D Young; Mei Q Ji; Larry Norton; Jeffrey A Drebin; Hongtao Zhang; Mark I Greene
Journal:  Cell Rep       Date:  2015-09-10       Impact factor: 9.423

10.  Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions.

Authors:  Elena Quaglino; Simona Rolla; Manuela Iezzi; Michela Spadaro; Piero Musiani; Carla De Giovanni; Pier Luigi Lollini; Stefania Lanzardo; Guido Forni; Remo Sanges; Stefania Crispi; Pasquale De Luca; Raffaele Calogero; Federica Cavallo
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.